The purpose of this study in a small group of non-stone-forming Chinese persons was to measure the levels of supersaturation with calcium oxalate and calcium phosphate and pH with the aim of confirming if any of the different short-term urine samples were better for risk evaluation than a 24-h sample. Nine normal men and 1 woman collected urine during 4 periods of the day. Period 1 between 08 and 12 h, Period 2 between 12 and 18 h, Period 3 between 18 and 22 h, and Period 4 between 22 and 08 h. Each sample was analysed for calcium, oxalate, citrate, magnesium and phosphate, and estimates of supersaturation with calcium oxalate (CaOx) and calcium phosphate (CaP) were expressed in terms of AP(CaOx) and AP(CaP) index. An estimate of the solute load of CaOx was also calculated. Urine composition for 24-h urine (Period 24) was obtained mathematically from the analysed variables. Urine composition corresponding to 14-h urine portions 22–12 h (Period 14 N) and 08–22 h (Period 14 D) were calculated. The lowest pH levels were recorded in Period 1 urine. The highest level of AP(CaOx) index was recorded during Period 1, and the product AP(CaOx) index × 107 × hydrogen ion concentration was significantly higher in Period 1 urine than in 24-h urine (p = 0.02). Also, the product SL(CaOx) × 107 × hydrogen ion concentration was significantly higher in Period 1 urine (p = 0.02). Low AP (CaP) index levels were recorded in Period 4, but also in all periods following dietary loads of calcium and phosphate. With the important reservation that the analytical results were obtained from non-stone-forming persons, the conclusion is that analysis of urine samples collected between 08 and 12 h might be an alternative to 24-h urine. The risk evaluation might advantageously be expressed either in terms of the product AP(CaOx) index × 107 × hydrogen ion concentration or the product SL(CaOx) × 107 × hydrogen ion concentration.

1.
Kok
DJ
.
The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?
Urolithiasis
.
2016 Feb
;
44
(
1
):
83
90
. .
2.
Robertson
WG
.
Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease
.
Urolithiasis
.
2016 Feb
;
44
(
1
):
9
26
. .
3.
Huang
Y
,
Zhang
YH
,
Chi
ZP
,
Huang
R
,
Huang
H
,
Liu
G
,
The handling of oxalate in the body and the origin of oxalate in calcium oxalate stones
.
Urol Int
.
2020
;
104
(
3–4
):
167
76
. .
4.
Tiselius
HG
.
Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?
Urolithiasis
.
2016 Feb
;
44
(
1
):
91
100
. .
5.
Tiselius
HG
,
Daudon
M
,
Thomas
K
,
Seitz
C
.
Metabolic work-up of patients with urolithiasis: indications and diagnostic algorithm
.
Eur Urol Focus
.
2017 Feb
;
3
(
1
):
62
71
. .
6.
Hesse
A
,
Tiselius
HG
,
Siener
R
,
Hoppe
B
.
Urinary stones – diagnosis, treatment and prevention of recurrence 3rd revised and enlarged edition
. In:
Hesse
A
,
Tiselius
HG
,
Siener
R
, editors.
Type of stone: calcium oxalate stones: biochemical investigations
.
Switzerland
:
Karger Basel
;
2009
. p.
42
8
.
7.
Tiselius
HG
.
Solution chemistry of supersaturation
. In:
Coe
FL
,
Favus
MJ
,
Pak
CYC
,
Parks
JH
,
Preminger
GM
, editors.
Kidney stones: medical and surgical management
.
Philadelphia/New York
:
Lippincott-Raven
;
1996
. p.
33
64
.
8.
Williams
JC
,
Gambaro
G
,
Rodgers
A
,
Asplin
J
,
Bonny
O
,
Costa-Bauzá
A
,
Urine and stone analysis for the investigation of the renal stone former: a consensus conference
.
Urolithiasis
.
2020
.
in press
. .
9.
Ahlstrand
C
,
Larsson
L
,
Tiselius
HG
.
Variations in urine composition during the day in patients with calcium oxalate stone disease
.
J Urol
.
1984 Jan
;
131
(
1
):
77
81
. .
10.
Tiselius
HG
.
An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease
.
Clin Chim Acta
.
1982 Jul 15
;
122
(
3
):
409
18
. .
11.
Tiselius
HG
.
Evaluation of patients with urinary tract stone disease
. In:
Talati
J
,
Tiselius
HG
,
Albala
D
,
Ze
Y
, editors.
Urolithiasis: basic concepts and clinical practice
.
London
:
Springer-Verlag
;
2012
. p.
671
82
.
12.
Tiselius
H-G
.
Medical evaluation of nephrolithiasis
.
Endocrinol Metab Clin North Am
.
2002 Dec
;
31
(
4
):
1031
50
. .
13.
Berg
C
,
Larsson
L
,
Tiselius
HG
.
The composition of four-hour urine samples from patients with calcium oxalate stone disease
.
Br J Urol
.
1987 Oct
;
60
(
4
):
301
6
. .
14.
Bek-Jensen
H
,
Tiselius
HG
.
Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers
.
Urol Res
.
1997
;
25
(
5
):
365
72
. .
15.
Hess
B
.
Renal stone clinic survey: calcium stone formers’ self-declared understanding of and adherence to physician’s recommendations
.
Urolithiasis
.
2017 Aug
;
45
(
4
):
363
70
.
16.
Fritsche
HM
,
Dötzer
K
.
Improving the compliance of the recurrent stone-former
.
Arab J Urol
.
2012 Sep
;
10
(
3
):
342
6
. .
17.
Wu
W
,
Yang
D
,
Tiselius
HG
,
Ou
L
,
Mai
Z
,
Chen
K
,
Collection and storage of urine specimens for measurement of urolithiasis risk factors
.
Urology
.
2015 Feb
;
85
(
2
):
299
303
. .
18.
Hattori
CM
,
Tiselius
HG
,
Heilberg
IP
.
Whey protein and albumin effects upon urinary risk factors for stone formation
.
Urolithiasis
.
2017 Oct
;
45
(
5
):
421
8
. .
19.
Tiselius
HG
.
Aspects on estimation of the risk of calcium oxalate crystallization in urine
.
Urol Int
.
1991
;
47
(
4
):
255
9
. .
20.
Tiselius
HG
.
A simplified estimate of the ion-activity product of calcium phosphate in urine
.
Eur Urol
.
1984
;
10
(
3
):
191
5
. .
21.
Tiselius
HG
.
Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?
Urolithiasis
.
2015 Jan
;(
43 Suppl 1
):
47
57
. .
22.
Tiselius
HG
.
A hypothesis of calcium stone formation: an interpretation of stone research during the past decades
.
Urol Res
.
2011 Aug
;
39
(
4
):
231
43
. .
23.
Tiselius
HG
,
Lindbäck
B
,
Fornander
AM
,
Nilsson
MA
.
Studies on the role of calcium phosphate in the process of calcium oxalate crystal formation
.
Urol Res
.
2009 Aug
;
37
(
4
):
181
92
. .
24.
Khan
SR
,
Pearle
MS
,
Robertson
WG
,
Gambaro
G
,
Canales
BK
,
Doizi
S
,
Kidney stones
.
Nat Rev Dis Primers
.
2016 Feb 25
;
2
:
16008
. .
25.
Tiselius
HG
.
The role of calcium phosphate in the development of randall’s plaques
.
Urolithiasis
.
2013 Oct
;
41
(
5
):
369
77
. .
26.
Højgaard
I
,
Tiselius
HG
.
Crystallization in the nephron
.
Urol Res
.
1999 Dec
;
27
(
6
):
397
403
.
27.
Ahlstrand
C
,
Tiselius
HG
,
Larsson
L
,
Hellgren
E
.
Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers
.
Br J Urol
.
1984 Jun
;
56
(
3
):
255
62
. .
28.
Tiselius
HG
.
Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule
.
Urol Res
.
1997
;
25
(
2
):
153
9
. .
29.
Ahlstrand
C
,
Tiselius
HG
,
Larsson
L
.
Studies on crystalluria in calcium oxalate stone formers
.
Urol Res
.
1984
;
12
(
2
):
103
6
. .
30.
Hallson
PC
,
Rose
GA
.
Procedure for the measurement of calcium oxalate and phosphate crystals in urine
.
Br J Urol
.
1988 Sep
;
62
(
3
):
199
202
. .
31.
Tiselius
HG
,
Höjgaard
I
.
Some aspects on the intratubular crystallisation of calcium salts
.
J Amer Soc Nephrol
.
1999 Nov
;
10
(
Suppl 14
):
S371
5
.
32.
Berg
C
,
Larsson
L
,
Tiselius
HG
.
The effects of a single evening dose of alkaline citrate on urine composition and calcium stone formation
.
J Urol
.
1992 Sep
;
148
(
3 Pt 2
):
979
85
. .
33.
Ahlstrand
C
,
Tiselius
HG
,
Larsson
L
.
Diurnal variation of urine composition in calcium oxalate stone disease during treatment with bendroflumethiazide
.
Eur Urol
.
1984
;
10
(
4
):
260
5
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.